HOME > Product > Futhan
Futhan has a potent inhibitory effect on a wide spectrum of proteases, i.e. coagulation-fibrinolysis system, kallikrein-kinin system, complement system and pancreatic enzymes.
Futhan effectively inhibits the aggravation of acute pancreatitis as well as ameliorating acute pancreatitis symptoms.
Futhan also shows excellent anticoagulating effects in preventing clotting during ECC (extracorporeal circulation) and thrombosis occurring in DIC (disseminated intravascular coagulation).
Futhan is a very safe anticoagulant for ECC in patients with a high risk of bleeding because of its short half life (5~8min after hemodialysis). Its anticoagulant activity is almost limited to the extracorporeal circuit.

Futhan inj. : 1 vial contains 10mg of nafamostat mesilate
Futhan50 inj. : 1 vial contains 50mg of nafamostat mesilate


1. For the amelioration of acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation of chronic pancreatitis, acute postoperative pancreatitis, ERCP-induced acute pancreatitis, traumatic pancreatitis)
2. Disseminated Intravascular Coagulation (DIC)
3. To prevent coagulation of blood during extracorporeal blood circulation (ex. hemodialysis, plasmapheresis) in patients with bleeding complications or tendency to bleed.


① For amelioration of acute pancreatitis symptoms.
Usually, 10mg of nafamostat mesilate dissolved in 500ml of 5% glucose solution is drip-infused intravenously over about 2 hours, once or twice a day. The dosage can be individually adjusted according to the severity of the symptoms.
② Disseminated Intravascular Coagulation (DIC)
Usually a one-day dose dissolved in 1000ml of 5% glucose solution is drip-infused intravenously over 24 hours at the rate of 0.06~0.20mg/kg/hr as nafamostat mesilate.
③ To prevent coagulation of blood during extracorporeal blood circulation
For priming, wash and fill the blood route with 500ml of saline containing 20mg of nafamostat mesilate. After beginning the extracorporeal circulation, continuously inject 20~50mg/hr of nafamostat mesilate dissolved in 5% glucose solution into the anticoagulant injection line. The dosage should be adjusted appropriately according to the patient's symptoms. The average dosage from clinical studies is 35mg/hr as nafamosat mesilate.


In the area of ECC
1. Futhan is the safest anticoagulant for patients at high risk of bleeding.
Due to its short half life, the activity of Futhan is almost limited to the extracorporeal circuit without affecting the coagulation ability of intracorporeal blood.
2. Dosaging & monitoring is convenient in comparison to conventional methods for patients at high risk of bleeding.
3. Futhan's excellent anticoagulating effect guarantees high efficiency of treatment.